Resource Center

Feb 1, 2018
  |  Press Release

Simulations Plus Launches Version 2.0 of PKPlus™

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical development from earliest discovery through all phases of clinical trials, today announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data.

Mark Pflieger, product manager for PKPlus, said: “From our initial release of PKPlus Version 1.0 in August 2016, we have paid careful attention to the feedback given by our customers and prospects. With their guidance and suggestions, and in close collaboration with our colleagues at Cognigen, we now have PKPlus Version 2.0, which contains many new features and improvements.”

New features & enhancements of PKPlus 2.0 include:

  • Non-Parametric Superposition (NPS)
  • Compartmental multi-dose simulation
  • Command line version (for fast, automated validation checks)
  • The ability to save map/report settings for use in other projects
  • Improvements to plotting and custom reports
  • Additional workflow refinements

John DiBella, president of the Lancaster division for Simulations Plus, added: “PKPlus continues to be the most affordable, commercially supported PK modeling platform in the marketplace, and we have decided with this new release to offer it to academic institutions at no cost to invest in the next generation of researchers who will be advancing the science of simulation and modeling. PKPlus v2.0 meets the requirements of a validated PK software, combining sophistication and ‘plug and play’ simplicity, at a fraction of the cost of competing tools. As more scientists work with the program, we’ll continue to listen and respond to update features and capabilities.”

Simulations Plus will host a webinar on Tuesday, February 20 at 8 a.m. PST (Los Angeles) to discuss the exciting new features in PKPlus 2.0. Please register here: www.simulations-plus.com/webinars/.

Contact Us About This Press Release